SpiN-Tec:一种基于T细胞的重组疫苗在受SARS-CoV-2关注变异株攻击的实验模型中安全、具有免疫原性且显示高效力
研究评估了以CTVad1(基于MF59的佐剂)佐剂的嵌合重组蛋白SpiN制成的SpiN-Tec疫苗的免疫原性、效力和安全性,旨在增强对SARS-CoV-2关注变异株的免疫力。在K18-hACE-2转基因小鼠和仓鼠中免疫可诱导针对SpiN蛋白及其组分RBD和N蛋白的高抗体滴度和细胞免疫应答。与紧急使用授权的COVID-19疫苗(ChAdOx1)进行异源初免/加强方案可增强循环中和抗体水平,并观察到对Wuhan分离株以及Delta和Omicron变异株的保护(表现为病毒载量降低和肺部病理减轻)。大鼠毒性和安全性测试表明疫苗安全,基于这些结果,SpiN-Tec的I/II期临床试验获批。
要点
- SpiN-Tec疫苗在K18-hACE-2转基因小鼠和仓鼠中诱导针对SpiN蛋白及其组分RBD和N蛋白的高抗体滴度和细胞免疫应答。
- 与ChAdOx1疫苗异源初免/加强可增强循环中和抗体水平。
- 观察到对Wuhan分离株及Delta和Omicron变异株的保护,表现为病毒载量降低和肺部病理减轻。
核心结论
- SpiN-Tec疫苗在实验模型中安全、具有免疫原性,并对SARS-CoV-2关注变异株显示高效力。
研究设计与样本
- 在K18-hACE-2转基因小鼠和仓鼠中评估SpiN-Tec疫苗的免疫原性、效力和安全性。
- 在大鼠中进行毒性和安全性测试。
主要发现
- 免疫K18-hACE-2转基因小鼠和仓鼠诱导了针对SpiN蛋白及其组分RBD和N蛋白的高抗体滴度和细胞免疫应答。
- 与ChAdOx1疫苗异源初免/加强方案增强了循环中和抗体水平。
- 观察到对Wuhan分离株以及Delta和Omicron变异株的保护,表现为病毒载量降低和肺部病理减轻。
- 大鼠毒性和安全性测试表明SpiN-Tec疫苗安全。
关键数值与推荐
- 基于大鼠安全性结果,SpiN-Tec的I/II期临床试验获批。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The emergence of new SARS-CoV-2 variants of concern associated with waning immunity induced by natural infection or vaccines currently in use suggests that the COVID-19 pandemic will become endemic. Investing in new booster vaccines using different platforms is a promising way to enhance protection and keep the disease under control. Here, we evaluated the immunogenicity, efficacy, and safety of the SpiN-Tec vaccine, based on a chimeric recombinant protein (SpiN) adjuvanted with CTVad1 (MF59-based adjuvant), aiming at boosting immunity against variants of concern of SARS-CoV-2. Immunization of K18-hACE-2 transgenic mice and hamsters induced high antibody titers and cellular immune response to the SpiN protein as well as to its components, RBD and N proteins. Importantly in a heterologous prime/boost protocol with a COVID-19 vaccine approved for emergency use (ChAdOx1), SpiN-Tec enhanced the level of circulation neutralizing antibodies (nAb). In addition to protection against the Wuhan isolate, protection against the Delta and Omicron variants was also observed as shown by reduced viral load and lung pathology. Toxicity and safety tests performed in rats demonstrated that the SpiN-Tec vaccine was safe and, based on these results, the SpiN-Tec phase I/II clinical trial was approved.
引用
- Hojo-Souza NS, de Castro JT, Rivelli GG, et al. SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concern. Vaccine. 2024. PMID: 39368129. doi:10.1016/j.vaccine.2024.126394
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。